Nuclear medicine program progress report for quarter ending March 31, 1994 Metadata

Metadata describes a digital item, providing (if known) such information as creator, publisher, contents, size, relationship to other resources, and more. Metadata may also contain "preservation" components that help us to maintain the integrity of digital files over time.

Title

  • Main Title Nuclear medicine program progress report for quarter ending March 31, 1994

Creator

  • Author: Knapp, F. F. Jr.
    Creator Type: Personal
  • Author: Ambrose, K. R.
    Creator Type: Personal
  • Author: Beets, A. L.
    Creator Type: Personal
  • Author: Lambert, C. R.
    Creator Type: Personal
  • Author: McPherson, D. W.
    Creator Type: Personal
  • Author: Mirzadeh, S.
    Creator Type: Personal
  • Author: Luo, H.
    Creator Type: Personal

Contributor

  • Sponsor: United States. Department of Energy.
    Contributor Type: Organization
    Contributor Info: USDOE, Washington, DC (United States)

Publisher

  • Name: Oak Ridge National Laboratory
    Place of Publication: Tennessee
    Additional Info: Oak Ridge National Lab., TN (United States)

Date

  • Creation: 1994-05-01

Language

  • English

Description

  • Content Description: The authors` new radioiodinated ``IQNP`` agent, an analogue of ``4-IQNB``, has a high affinity for the muscarinic-cholinergic receptor (m-AChR). Iodine is stabilized in ``IQNP`` by attachment as a vinyl iodide. To evaluate the potential usefulness of a [Br-76]-labeled analogue as a candidate for positron emission tomography (PET), they have synthesized the trans-3-bromopropenyl analogue (BrQNP) and evaluated its ability in vivo to block uptake of [I-125]-Z-(R,R)-IQNP. Reaction of bromine with the trans-tributylstannyl substrate prepared from ethyl -{alpha}-hydroxy -{alpha}-phenyl-{alpha}-(1-propyn-3-yl)acetate, followed by column purification and transesterification with (R,S)-3-quinuclidinol gave BrQNP. Female rats were pre-treated with the oxalate salt of BrQNP one hour prior to I.V. injection of [I-125]-IQNP. While the brain and heart uptake in BrQNP pre-treated animals was significantly decreased, the control animals showed the expected high uptake of IQNP in these tissues. The ease of preparation and ability to block m-AChR suggest that [Br-76]-labeled BrQNP is a potential candidate for PET studies. In this report, the authors also summarize their current on-going collaborative studies assessing the usefulness of various rhenium-188-labeled therapeutic agents. In addition, collaborative programs have been established to evaluate rhenium-188-labeled particles for treatment of arthritis (synovectomy), treatment of bone pain resulting from cancer metastheses with rhenium-188-phosphonates (palliation), and other applications.
  • Physical Description: 14 p.

Subject

  • Keyword: Research Programs
  • Keyword: Radioimmunotherapy
  • Keyword: Nuclear Medicine
  • Keyword: Radiopharmaceuticals
  • STI Subject Categories: 62 Radiology And Nuclear Medicine
  • Keyword: Progress Report
  • Keyword: Therapeutic Uses
  • Keyword: Diagnostic Uses 550601
  • Keyword: Chemical Preparation
  • Keyword: Unsealed Radionuclides In Diagnostics
  • Keyword: Unsealed Radionuclides In Therapy
  • Keyword: Uptake
  • STI Subject Categories: 550604

Source

  • Other Information: PBD: 1 May 1994

Collection

  • Name: Office of Scientific & Technical Information Technical Reports
    Code: OSTI

Institution

  • Name: UNT Libraries Government Documents Department
    Code: UNTGD

Resource Type

  • Report

Format

  • Text

Identifier

  • Other: DE94011796
  • Report No.: ORNL/TM--12707
  • Grant Number: AC05-84OR21400
  • DOI: 10.2172/10151067
  • Office of Scientific & Technical Information Report Number: 10151067
  • Archival Resource Key: ark:/67531/metadc1313353

Note

  • Display Note: OSTI as DE94011796; Paper copy available at OSTI: phone, 865-576-8401, or email, reports@adonis.osti.gov